Nothing Special   »   [go: up one dir, main page]

DE13156663T1 - NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen - Google Patents

NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen Download PDF

Info

Publication number
DE13156663T1
DE13156663T1 DE13156663.0T DE13156663T DE13156663T1 DE 13156663 T1 DE13156663 T1 DE 13156663T1 DE 13156663 T DE13156663 T DE 13156663T DE 13156663 T1 DE13156663 T1 DE 13156663T1
Authority
DE
Germany
Prior art keywords
fumarate
administered
monomethyl
dimethyl fumarate
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE13156663.0T
Other languages
English (en)
Inventor
Matvey E. Lukashev
Gilmore O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE13156663(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of DE13156663T1 publication Critical patent/DE13156663T1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung Multipler Sklerose, wobei die Zusammensetzung aus Folgendem besteht:(a) Fumarsäuredimethylester oder Fumarsäuremonomethylester und(b) einem oder mehreren pharmazeutisch unbedenklichen Arzneimittelträgern, wobei die Zusammensetzung einem Patienten mit Behandlungsbedarf bei Multipler Sklerose oral zu verabreichen ist und wobei die zu verabreichende Dosis Fumarsäuredimethylester oder Fumarsäuremonomethylester etwa 480 mg bis etwa 720 mg pro Tag beträgt.

Claims (20)

  1. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung Multipler Sklerose, wobei die Zusammensetzung aus Folgendem besteht: (a) Fumarsäuredimethylester oder Fumarsäuremonomethylester und (b) einem oder mehreren pharmazeutisch unbedenklichen Arzneimittelträgern, wobei die Zusammensetzung einem Patienten mit Behandlungsbedarf bei Multipler Sklerose oral zu verabreichen ist und wobei die zu verabreichende Dosis Fumarsäuredimethylester oder Fumarsäuremonomethylester etwa 480 mg bis etwa 720 mg pro Tag beträgt.
  2. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 1, wobei die Zusammensetzung aus Fumarsäuredimethylester und einem oder mehreren pharmazeutisch unbedenklichen Arzneimittelträgern besteht.
  3. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 1, wobei die Zusammensetzung aus Fumarsäuremonomethylester und einem oder mehreren pharmazeutisch unbedenklichen Arzneimittelträgern besteht.
  4. Pharmazeutische Zusammensetzung zur Verwendung nach irgendeinem der Ansprüche 1 bis 3, wobei die zu verabreichende Dosis Fumarsäuredimethylester oder Fumarsäuremonomethylester etwa 480 mg pro Tag beträgt.
  5. Pharmazeutische Zusammensetzung zur Verwendung nach irgendeinem der Ansprüche 1 bis 4, wobei die Zusammensetzung in Form einer Tablette, einer Suspension oder einer Kapsel zu verabreichen ist.
  6. Pharmazeutische Zusammensetzung zur Verwendung nach irgendeinem der Ansprüche 1 bis 5, wobei der Fumarsäuredimethylester und/oder Fumarsäuremonomethylester in getrennten Verabreichungen von 2, 3, 4 oder 6 gleichen Dosen zu verabreichen ist.
  7. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 6, wobei die Dosis von Fumarsäuredimethylester oder Fumarsäuremonomethylester in getrennten Verabreichungen von 2 gleichen Dosen zu verabreichen ist.
  8. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 6, wobei die Dosis von Fumarsäuredimethylester oder Fumarsäuremonomethylester in getrennten Verabreichungen von 3 gleichen Dosen zu verabreichen ist.
  9. Pharmazeutische Zusammensetzung zur Verwendung nach irgendeinem der Ansprüche 1 bis 8, wobei die Zusammensetzung dem Patienten 5, 10, 12, 20, 40, 52, 100 oder 200 Wochen lang oder länger zu verabreichen ist.
  10. Pharmazeutische Zusammensetzung zur Verwendung nach irgendeinem der Ansprüche 1 bis 9, wobei die Zusammensetzung dem Patienten für mindestens 12 Wochen zu verabreichen ist.
  11. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung bei der Behandlung Multipler Sklerose, wobei der Fumarsäuredimethylester oder Fumarsäuremonomethylester das einzige zu verabreichende Neuroprotektivum ist und wobei der Fumarsäuredimethylester oder Fumarsäuremonomethylester einem Patienten mit Behandlungsbedarf bei Multipler Sklerose mit einer Dosis von etwa 480 mg bis etwa 720 mg pro Tag oral zu verabreichen ist.
  12. Fumarsäuredimethylester zur Verwendung nach Anspruch 11, wobei der Fumarsäuredimethylester das einzige zu verabreichende Neuroprotektivum ist.
  13. Fumarsäuremonomethylester zur Verwendung nach Anspruch 11, wobei der Fumarsäuremonomethylester das einzige zu verabreichende Neuroprotektivum ist.
  14. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach irgendeinem der Ansprüche 11 bis 13, wobei die Dosis etwa 480 mg pro Tag beträgt.
  15. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach irgendeinem der Ansprüche 11 bis 14, wobei der Fumarsäuredimethylester oder Fumarsäuremonomethylester in Form einer Tablette, einer Suspension oder einer Kapsel zu verabreichen ist.
  16. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach irgendeinem der Ansprüche 11 bis 15, wobei die Dosis in getrennten Verabreichungen von 2, 3, 4 oder 6 gleichen Dosen zu verabreichen ist.
  17. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach Anspruch 16, wobei die Dosis in getrennten Verabreichungen von 2 gleichen Dosen zu verabreichen ist.
  18. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach Anspruch 16, wobei die Dosis in getrennten Verabreichungen von 3 gleichen Dosen zu verabreichen ist.
  19. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach irgendeinem der Ansprüche 11 bis 18, wobei der Fumarsäuredimethylester oder Fumarsäuremonomethylester dem Patienten 5, 10, 12, 20, 40, 52, 100 oder 200 Wochen lang oder länger zu verabreichen ist.
  20. Fumarsäuredimethylester oder Fumarsäuremonomethylester zur Verwendung nach irgendeinem der Ansprüche 11 bis 19, wobei der Fumarsäuredimethylester oder Fumarsäuremonomethylester dem Patienten mindestens 12 Wochen lang zu verabreichen ist.
DE13156663.0T 2007-02-08 2008-02-07 NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen Pending DE13156663T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88892107P 2007-02-08 2007-02-08
USUS20070888921P 2007-02-08
EP13156663.0A EP2629097A1 (de) 2007-02-08 2008-02-07 NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen

Publications (1)

Publication Number Publication Date
DE13156663T1 true DE13156663T1 (de) 2022-07-14

Family

ID=39682314

Family Applications (2)

Application Number Title Priority Date Filing Date
DE13156663.0T Pending DE13156663T1 (de) 2007-02-08 2008-02-07 NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen
DE13169139.6T Pending DE13169139T1 (de) 2007-02-08 2008-02-07 Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE13169139.6T Pending DE13169139T1 (de) 2007-02-08 2008-02-07 Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose

Country Status (19)

Country Link
US (8) US20110112196A1 (de)
EP (10) EP2680008A1 (de)
CY (4) CY1114340T1 (de)
DE (2) DE13156663T1 (de)
DK (3) DK2653873T3 (de)
ES (3) ES2424022T3 (de)
FI (2) FI2629097T1 (de)
FR (2) FR14C0050I1 (de)
HK (1) HK1139204A1 (de)
HR (2) HRP20220902T3 (de)
HU (1) HUS2300001I1 (de)
LT (2) LT2653873T (de)
LU (1) LU92487I2 (de)
NO (2) NO2014015I1 (de)
PL (2) PL2653873T3 (de)
PT (2) PT2653873T (de)
RS (2) RS63489B1 (de)
SI (2) SI2137537T1 (de)
WO (1) WO2008097596A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
RU2313339C2 (ru) 2003-09-09 2007-12-27 Фумафарм Аг Применение производных фумаровой кислоты для лечения сердечной недостаточности и астмы
HUE028342T2 (en) 2004-10-08 2016-12-28 Forward Pharma As Pharmaceutical preparations containing controlled release fumaric acid ester
DK2139467T3 (da) * 2007-02-08 2017-01-02 Biogen Ma Inc Neurobeskyttelse i demyelinisationssygdomme
DE13156663T1 (de) 2007-02-08 2022-07-14 Biogen Ma Inc. NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen
MY158798A (en) 2008-01-11 2016-11-15 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
US8258329B2 (en) 2008-04-18 2012-09-04 Reata Pharmaceuticals, Inc. Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
TWI442925B (zh) 2008-04-18 2014-07-01 Reata Pharmaceuticals Inc 抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物
US7943778B2 (en) 2008-04-18 2011-05-17 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
CA2731650A1 (en) 2008-07-22 2010-01-28 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
NZ602496A (en) 2008-08-19 2013-09-27 Xenoport Inc Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
EP3090733A1 (de) 2009-01-09 2016-11-09 Forward Pharma A/S Pharmazeutische formulierung mit einem oder mehreren fumarsäureestern in einer erosionsmatrix
NZ595941A (en) * 2009-04-29 2014-02-28 Biogen Idec Inc Treatment of neurodegeneration and neuroinflammation
SG182414A1 (en) 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
ES2679918T3 (es) 2010-02-18 2018-08-31 Vtv Therapeutics Llc Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
EP2648732A4 (de) * 2010-12-07 2014-04-30 Teva Pharma Verwendung von laquinimod zur ermüdungsverringerung, zur verbesserung des funktionellen status und zur verbesserung der lebensqualität bei patienten mit multipler sklerose
MX2013006902A (es) 2010-12-17 2013-10-17 Reata Pharmaceuticals Inc Enonas triciclicas de pirazolilo y pirimidinilo como moduladores antioxidantes de la inflamacion.
SG193404A1 (en) 2011-03-11 2013-10-30 Reata Pharmaceuticals Inc C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2012145420A1 (en) * 2011-04-18 2012-10-26 Rutgers, The State University Of New Jersey Composition, synthetic process and use of new antioxidant inflammation modulators
US20140142095A1 (en) * 2011-04-28 2014-05-22 Serket Pharma, Llc Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
CN103732062A (zh) * 2011-05-26 2014-04-16 比奥根艾迪克Ma公司 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
AU2012267524A1 (en) 2011-06-08 2013-12-12 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
US9421273B2 (en) 2011-12-16 2016-08-23 Biogen Ma Inc. Silicon-containing fumaric acid esters
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
WO2013144077A1 (en) * 2012-03-30 2013-10-03 Nestec S.A. 4-oxo-2-pentenoic acid and brain health
RS56154B1 (sr) 2012-04-27 2017-11-30 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
CA2882727A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
LT2892912T (lt) 2012-09-10 2019-07-10 Reata Pharmaceuticals, Inc. Oleanolio rūgšties c17-alkandiilo ir alkendiilo dariniai bei jų panaudojimo būdai
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US10054583B2 (en) * 2012-10-10 2018-08-21 Temple University Of The Commonwealth System Of Higher Education Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
WO2014100728A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium substituted fumarate derivatives
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
NZ737435A (en) 2013-03-14 2019-02-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) * 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
ES2526979B1 (es) * 2013-07-17 2015-10-28 Fundación Para La Investigación Biomédica Del Hospital Universitario De La Princesa Uso del 3-(2-isotiocianatoetil)-5-metoxi-1H-indol para el tratamiento de enfermedades neurodegenerativas
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
EP3777980B1 (de) 2013-10-29 2023-12-06 President and Fellows of Harvard College Nuclear factor erythroid 2-like 2 (nrf2) zur verwendung in der behandlung der altersbedingten makuladegeneration
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP2924127A1 (de) 2014-03-27 2015-09-30 Université Paul Sabatier Toulouse III Verfahren und Kit zur Prognose von durch das OPA1 Gen induzierte Erkrankungen, z.B. Optikusatrophie
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
WO2016160635A1 (en) 2015-03-27 2016-10-06 Sytheon Limited Compositions and methods for treating psoriasis
AU2016273068A1 (en) 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
CN105087644A (zh) * 2015-07-23 2015-11-25 山东大学 一种高通量筛选具有Nrf2激活活性的化合物的方法
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
AU2016326704B2 (en) 2015-09-23 2021-01-28 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
WO2018223098A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
EP3630132A1 (de) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Erzeugnisse und behandlungsverfahren unter verwendung von adoptiver zelltherapie
US20210071258A1 (en) 2017-09-01 2021-03-11 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
EP4124658A3 (de) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
EP4454654A2 (de) 2017-10-16 2024-10-30 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
AU2019299861A1 (en) 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US20210361318A1 (en) 2018-07-02 2021-11-25 Voyager Therapeutics, Inc. Cannula system and use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
MX2021006238A (es) 2018-11-30 2021-10-01 Juno Therapeutics Inc Metodos para tratamiento que usan terapia celular adoptiva.
FI3886894T3 (fi) 2018-11-30 2024-05-24 Juno Therapeutics Inc Menetelmiä annosteluun ja b-solumaligniteettien hoitoon adoptiivisessa soluterapiassa
AU2020395318A1 (en) 2019-12-06 2022-06-09 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2021183905A1 (en) * 2020-03-13 2021-09-16 Simard Marc J Methods of treating multiple sclerosis

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
JPS5824104B2 (ja) 1977-12-06 1983-05-19 博衛 小川 フマル酸製剤
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
DE3127432A1 (de) 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
CH664150A5 (de) 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
JPS61194020A (ja) 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5214196A (en) 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5242905A (en) 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
WO1992012952A1 (en) 1991-01-18 1992-08-06 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5459667A (en) 1993-01-22 1995-10-17 Sumitomo Electric Industries, Ltd. Navigation apparatus for informing vehicle driver of information regarding travel route
CA2164837A1 (en) 1993-06-08 1994-12-22 Raymond K. Brown Therapeutic compositions and methods of use
JPH06345644A (ja) 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
US5407772A (en) 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
ATE201680T1 (de) 1994-03-16 2001-06-15 Cenes Ltd 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
WO1997011092A1 (fr) 1994-04-07 1997-03-27 Nippon Shinyaku Co., Ltd. Derives de phosphates de cyclosporine et composition medicinale
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
JP2535141B2 (ja) 1995-01-17 1996-09-18 中外製薬株式会社 フマル酸含有徐放性製剤
KR19990044618A (ko) 1995-09-13 1999-06-25 다케다 야쿠힌 고교 가부시키가이샤 면역억제제
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
JP4004567B2 (ja) 1996-02-14 2007-11-07 アステラス製薬株式会社 Ｗｂ２６６３ｂ物質を含有する免疫抑制剤
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
PL330149A1 (en) 1996-05-22 1999-04-26 Univ Alberta Bonding chemokins of type ii proteins and method of applying them
WO1997048405A1 (fr) 1996-06-21 1997-12-24 Jury Evgenievich Belyaev Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
EP2298350A3 (de) 1996-07-26 2011-06-08 Susan P. Perrine Zusammensetzung enthaltend einen induzierenden wikstoff und einen antiviralen wirkstoff zur behandlung von viralen störungen
AU5474198A (en) 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
US6537969B1 (en) 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
CA2399623A1 (en) 2000-02-11 2001-08-16 Philadelphia Health And Education Corporation Differentiation of bone marrow cells into neuronal cells and uses therefor
WO2002002190A2 (en) 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
US6451667B1 (en) 2000-12-21 2002-09-17 Infineon Technologies Ag Self-aligned double-sided vertical MIMcap
EE05472B1 (et) 2001-01-12 2011-10-17 Fumapharm Ag Fumaarhappeamiidide kasutamine ravimina
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
PL363392A1 (en) 2001-02-14 2004-11-15 Matthias Rath Compositions of biochemical compounds involved in bioenergy metabolism of cells
RU2189813C1 (ru) 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Лекарственное средство антигипоксического действия
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
WO2003032969A2 (en) 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
RU2313339C2 (ru) 2003-09-09 2007-12-27 Фумафарм Аг Применение производных фумаровой кислоты для лечения сердечной недостаточности и астмы
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
HUE028342T2 (en) 2004-10-08 2016-12-28 Forward Pharma As Pharmaceutical preparations containing controlled release fumaric acid ester
WO2006050730A1 (en) 2004-11-10 2006-05-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
AU2005306399B2 (en) 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
US7638119B2 (en) 2004-12-02 2009-12-29 Wisconsin Alumni Research Foundation Method of diminishing the symptoms of neurodegenerative disease
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
MX2007009946A (es) 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
US7868005B2 (en) 2005-02-16 2011-01-11 Schering Corporation Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
MX2007009948A (es) 2005-02-16 2007-09-26 Schering Corp Pierazin-piperidinas sustituidas con piridilo y fenilo conectados por aminos con actividad antagonista de cxcr3.
PE20061093A1 (es) 2005-02-16 2006-11-10 Schering Corp Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
AU2006214480A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
KR20070107040A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 헤테로아릴-치환된피라지닐-피페라진-피페리딘
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
EP1959969A2 (de) * 2005-07-01 2008-08-27 The Johns Hopkins University Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit oxidativem stress
EP1915334A2 (de) 2005-07-07 2008-04-30 Aditech Pharma AB Neue salze von fumarsäuremonoalkylestern und deren pharmazeutische verwendung
US20100144651A1 (en) 2005-07-07 2010-06-10 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP1951206A1 (de) 2005-10-07 2008-08-06 Aditech Pharma AB Pharmazeutische zusammensetzung mit kontrollierter freisetzung mit einem fumarsäureester
EP1940382A2 (de) 2005-10-07 2008-07-09 Aditech Pharma AB Kombinationstherapie mit fumarsäureestern zur behandlung von autoimmunkrankheiten und/oder entzündlichen erkrankungen
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
DK2139467T3 (da) 2007-02-08 2017-01-02 Biogen Ma Inc Neurobeskyttelse i demyelinisationssygdomme
DE13156663T1 (de) 2007-02-08 2022-07-14 Biogen Ma Inc. NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen
NZ595941A (en) 2009-04-29 2014-02-28 Biogen Idec Inc Treatment of neurodegeneration and neuroinflammation
HUE025878T2 (en) 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases
JP2013221921A (ja) 2012-04-19 2013-10-28 Heidenhain Kk ロータリーエンコーダ

Also Published As

Publication number Publication date
ES2916649T1 (es) 2022-07-04
HRP20220902T3 (hr) 2022-10-14
EP2629097A1 (de) 2013-08-21
PL2137537T3 (pl) 2013-10-31
NO2014015I1 (no) 2014-06-26
WO2008097596A3 (en) 2008-12-11
US20120196931A1 (en) 2012-08-02
LU92487I2 (fr) 2015-11-02
EP2680007A1 (de) 2014-01-01
CY1114340T1 (el) 2016-08-31
PT2653873T (pt) 2022-07-26
US20150366803A1 (en) 2015-12-24
EP2680009A1 (de) 2014-01-01
EP2680010A1 (de) 2014-01-01
CY2014026I2 (el) 2016-10-05
DK2653873T3 (da) 2022-07-25
US20130303613A1 (en) 2013-11-14
FR14C0050I1 (fr) 2014-08-08
ES2916604T1 (es) 2022-07-04
FR23C1003I1 (fr) 2023-03-10
FR23C1003I2 (fr) 2024-01-12
US20200016072A1 (en) 2020-01-16
HK1139204A1 (en) 2010-09-10
PL2653873T1 (pl) 2022-07-04
NO2023001I1 (no) 2023-01-02
EP2137537A2 (de) 2009-12-30
DE13169139T1 (de) 2022-07-14
SI2653873T1 (sl) 2022-09-30
CY2023002I1 (el) 2023-06-09
DK2137537T3 (da) 2013-07-29
EP4137819A1 (de) 2023-02-22
RS63489B1 (sr) 2022-09-30
WO2008097596A2 (en) 2008-08-14
HRP20130707T1 (en) 2013-09-30
EP2680008A1 (de) 2014-01-01
PL2653873T3 (pl) 2022-08-22
PT2137537E (pt) 2013-08-22
DK2653873T1 (da) 2022-05-30
HUS2300001I1 (hu) 2023-02-28
EP2680006A1 (de) 2014-01-01
US20110112196A1 (en) 2011-05-12
EP2137537B8 (de) 2016-06-01
US20130317103A1 (en) 2013-11-28
CY2023004I2 (el) 2023-06-09
SI2137537T1 (sl) 2013-10-30
EP2518511A1 (de) 2012-10-31
FIC20230002I1 (fi) 2023-01-16
DK2629097T1 (da) 2022-05-30
LT2653873T (lt) 2022-10-10
US20120259012A1 (en) 2012-10-11
EP2137537B1 (de) 2013-05-29
US8399514B2 (en) 2013-03-19
EP2653873B1 (de) 2022-07-20
CY2023004I1 (el) 2023-06-09
ES2424022T3 (es) 2013-09-26
LTPA2023503I1 (de) 2023-02-10
US20180263906A1 (en) 2018-09-20
ES2916649T3 (es) 2022-09-21
CY2014026I1 (el) 2016-10-05
FI2629097T1 (fi) 2022-06-15
EP2653873A1 (de) 2013-10-23
RS52922B (en) 2014-02-28
EP2653873B8 (de) 2022-08-24

Similar Documents

Publication Publication Date Title
DE13156663T1 (de) NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen
DE69710390T2 (de) Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren
DE05852057T1 (de) Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
DE60026146T2 (de) Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
SA01210740A (ar) تركيب على شكل جرعات تؤخذ عن طريق الفم ممتدة الانطلاق.
EP0332918A2 (de) Erzeugnisse, enthaltend einen Calciumantagonisten und einen Lipidsenker
JP2005515964A5 (de)
DE69926804T2 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
EP1648433A1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
EP3673903A1 (de) Tapentadol zur schmerzbehandlung bei arthrose
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
TW200603816A (en) Risedronate compositions and their methods of use
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
CH702339B1 (de) Kombination von Paracetamol und Ibuprofen zur Behandlung von Osteoarthritis.
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
EP1461042B1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60203106T2 (de) Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen
WO2018151285A1 (ja) 掻痒性皮膚疾患の予防又は治療薬
SA522441056B1 (ar) مُركّب جديد من كبريتات [2-(داي ميثيل أمينو)-2-فينيل بيوتيل]-3، 4، 5-تراي ميثوكسي بنزوات 4-ميثيل-2h-كرومين-2-ون-7-يل واستخدامه
JP2018506590A (ja) トリパルス放出型賦活薬製剤
CN104415026A (zh) 氘代富马酸衍生物在治疗多发性硬化症中的应用
Patil et al. Efficacy of hyaluronidase and dexamethasone intralesional injections in the management of oral submucous fibrosis
WO1993024130A1 (de) (-)-metrifonat enthaltendes arzneimittel
DE60121142T2 (de) Zusammensetzung die paracetamol und niflumic säure enthält
JPS5824520A (ja) 精神病治療薬